• 1
    Bonavida B, Tsuchitani T, Safrit JT, Zighelboim J. Hierarchy of tumor cell sensitivity and resistance to cytolysis by TNF, cytotoxic cells, bacterial toxins, and cytotoxic drugs. In: BonavidaB, GrangerG, editors. Tumor necrosis factor: structure, mechanism of action, role in disease and therapy. Basel: S Karger, 1990: 12532.
  • 2
    Safrit JT, Bonavida B. Hierarchy of sensitivity and resistance of tumor cells to cytotoxic effector cells, cytokines, drugs, and toxins. Cancer Immunol Immunother 1992; 34: 3218.
  • 3
    Rosenberg B, Van Camp L, Trosko JE, Mansour VH. Platinum compounds: a new class of potent antitumor agents. Nature 1983; 222: 2856.
  • 4
    Zambetti M, Gianni L, Di Re F, Spatti G, Fontanelli R, Escobedo A, et al. Cisplatin and cyclophosphamide in advanced ovarian carcinoma: activity and toxicity of an ambulatory regimen. Am J Clin Oncol 1990; 13: 199203.
  • 5
    Piccart MJ, Nogaret JM, Marcelis L, Longree H, Ries F, Kains JP, et al. Cisplatin combined with carboplatin: new way of intensification of platinum dose in the treatment of advanced ovarian cancer. Belgian Study Group for Ovarian Carcinoma. J Natl Cancer Inst 1990; 82: 7037.
  • 6
    Sarrita JA. A new protocol for ovarian carcinoma. Eur J Gynecol Oncol 1988; 9: 407.
  • 7
    Pascoe JM, Roberts JJ. Interactions between mammalian cell DNA and inorganic platinum compounds: I. DNA interstrand cross-linking and cytotoxic properties of platinum (II) compounds. Biochem Pharmacol 1974; 23: 134557.
  • 8
    Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis in tumors. Proc Natl Acad Sci U S A 1975; 72: 366670.
  • 9
    Old LJ. Tumor necrosis factor (TNF). Science 1985; 230: 6305.
  • 10
    Sugarman BJ, Aggarwal BB, Hass PE, Figari IS, Palladino MA, Shepard HM. Recombinant human tumor necrosis factor-α: effect on proliferation of normal and transformed cells in vitro. Science 1985; 230: 9436.
  • 11
    Ruggiero V, Latham K, Baglioni C. Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells. J Immunol 1987; 138: 271125.
  • 12
    Shirai T, Yamaguchi H, Ito H, Todd CW, Wallace RB. Cloning and expression in Escherichia coli of the gene for human tumor necrosis factor. Nature 1985; 313: 8036.
  • 13
    Wang AM, Creasy AA, Ladner MB, Lin LS, Strickle J, Vanarsdell JN, et al. Molecular cloning of the complementary DNA for tumor necrosis factor. Science 1985; 228: 14954.
  • 14
    Feinberg B, Kurzurock R, Talpaz M, Blick M, Saks S, Gutterman JU. Phase I trial of intravenously administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988; 6: 132834.
  • 15
    Lenk H, Tanneberger S, Muller U, Ebert J, Shiga T. Phase II clinical trial of high-dose recombinant human tumor necrosis factor. Cancer Chemother Pharmacol 1989; 24: 3915.
  • 16
    Matthews N, Neale ML, Jackson SK, Stark JM. Tumor cell killing by tumor necrosis factor: inhibition by anaerobic conditions, free radical scavengers, and inhibitors of arachidonate metabolism. Immunology 1987; 62: 1535.
  • 17
    Schmid DS, Honung R, McGrath KM, Paul N, Ruddle NH. Target cell DNA fragmentation is mediated by lymphotoxin and TNF. Lymphokine Res 1987; 6: 195202.
  • 18
    Williamson BD, Carswell EA, Rubin BY, Pendergast JS, Old LJ. Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci U S A 1983; 80: 5397401.
  • 19
    Watanabe N, Niitsu Y, Neda H, Sone H, Yamauchi N, Umetsu T, et al. Antitumor effect of tumor necrosis factor against various primarily cultured human cancer cells. Jpn J Cancer Res 1985; 76: 11159.
  • 20
    Alexander RB, Nelson WG, Coffey DS. Synergistic enhancement by tumor necrosis factor of in vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res 1987; 47: 24036.
  • 21
    Krosnick JA, Mule JJ, McIntosh JK, Rosenberg SA. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo. Cancer Res 1989; 49: 372933.
  • 22
    Bonavida B, Tsuchitani T, Zighelboim J, Berek J. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells. Gynecol Oncol 1990; 38: 3339.
  • 23
    Mizutani Y, Nio Y, Fukumoto M, Yoshida O. Effects of bacillus Calmette-Guerin on cytotoxic activities of peripheral blood lymphocytes against human T24 lined and freshly isolated autologous urinary bladder transitional carcinoma cells in patients with urinary bladder cancer. Cancer 1992; 69: 53745.
  • 24
    Mizutani Y, Nio Y, Yoshida O. The streptococcal preparation OK-432 specifically augments the susceptibility of human urinary bladder tumor cells to the autologous peripheral blood lymphocytes. Cancer 1992; 69: 29993007.
  • 25
    Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, et al. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988; 48: 589601.
  • 26
    Goldberg DA. Isolation and partial characterization of the Drosophila alcohol dehydrogenase gene. Proc Natl Acad Sci U S A 1980; 77: 57948.
  • 27
    Fienberg AP, Vogelstein B. A technique for radiolabelling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983; 132: 613.
  • 28
    Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162: 1569.
  • 29
    Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 1981; 35: 26990.
  • 30
    Rubin BY, Anderson SL, Sullivan SA, Williamson BD, Carswell EA, Old LJ. Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor necrosis factor. J Exp Med 1986; 164: 13505.
  • 31
    Spriggs DR, Imamura K, Rodriguez C, Horiguchi J, Kufe DW. Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc Natl Acad Sci U S A 1987; 84: 65636.
  • 32
    Spriggs DR, Imamura K, Rodriguez C, Sariban E, Kufe DW. Tumor necrosis factor expression in human epithelial tumor cell lines. J Clin Invest 1988; 81: 45560.
  • 33
    Vanhaesebroek B, Decoster E, Ostade XV, Bladel SV, Lenaersts A, Roy FV, et al. Expression of an exogenous tumor necrosis factor (TNF) gene in TNF-sensitive cell lines confers resistance to TNF-mediated cell lysis. J Immunol 1992; 148: 278594.
  • 34
    Watanabe N, Niitsu Y, Yamauchi N, Ohtsuka Y, Sone H, Neda H, et al. Synergistic cytotoxicity of recombinant human TNF and various anti-cancer drugs. Immunopharmacol Immunotoxicol 1988; 10: 11727.
  • 35
    Mutch DG, Powell CB, Kao M, Collins JL. In vitro analysis of the anticancer potential of tumor necrosis factor in combination with cisplatin. Gynecol Oncol 1989; 34: 32833.
  • 36
    Soranzo C, Perego P, Zunino F. Effect of tumor necrosis factor on human tumor cells sensitive and resistant to cytotoxic drugs, and its interaction with chemotherapeutic agents. Anti-Cancer Drugs 1990; 1: 15763.
  • 37
    Richon VM, Schulte N, Eastmen A. Multiple mechanisms of resistance to cis-diamminedichloroplatinum (II) in murine leukemia L1210 cells. Cancer Res 1987; 47: 205661.
  • 38
    Waud WR. Differential uptake of cis-diamminedichloroplatinum (II) by sensitive and resistant murine L1210 leukemia cells. Cancer Res 1987; 47: 654955.
  • 39
    Metcalfe SA, Cain K, Hill BT. Possible mechanisms for differences in sensitivity to cis-platinum in human prostate tumor cell lines. Cancer Lett 1986; 31: 1639.
  • 40
    Hromas RA, Andrews PA, Murphy MP. Glutathione depletion reverses cisplatin resistance in murine L1210 leukemia cells. Cancer Lett 1987; 34: 913.
  • 41
    Andrews PA, Murphy MP, Howell SB. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 1988; 19: 14954.
  • 42
    Taylor DM, Tew KD, Jones JD. Effects of cisdichlorodiammine platinum (II) on DNA synthesis in kidney and other tissues of normal and tumor-bearing rats. Eur J Cancer 1976; 12: 24954.
  • 43
    Roos IAG, Arnold MC. Interaction of an anti-tumor active platinum complex with DNA. J Clin Hematol Oncol 1977; 7: 37488.
  • 44
    Pera MF, Rawlings CJ, Roberts JJ. The role of DNA repair in the recovery of human cells from cisplatin toxicity. Chem Biol Interact 1981; 37: 24561.
  • 45
    Beutler B, Krochin R, Milsark IW, Leudke C, Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986; 232: 97780.
  • 46
    Kronke M, Hensel G, Schluter C, Scheurich P, Schutze S, Pfizenmeir K. Tumor necrosis factor and lymphotoxin gene expression in human tumor cell lines. Cancer Res 1988; 48: 541721.
  • 47
    Lie LF. CDNA topoisomerases: enzymes that catalyze the breaking and rejoining of DNA. CRC Crit Rev Biochem 1983; 15: 124.
  • 48
    Safrit JT, Bonavida B. Sensitivity of resistant human tumor cell lines to TNF and Adriamycin used in combination: correlation between downregulation of TNF-mRNA induction and overcoming resistance. Cancer Res 1992; 52: 66307.
  • 49
    Morimoto H, Safrit JT, Bonavida, B. Synergistic effect of tumor necrosis factor-α and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines. J Immunol 1991; 147: 260916.
  • 50
    Kull FC Jr., Cuatrecasas P. Possible requirement of internalization in the mechanism of in vitro cytotoxicity in tumor necrosis factor serum. Cancer Res 1981; 41: 48859.
  • 51
    Darzynkiewicz Z, Carter SP, Old SP. Effects of recombinant tumor necrosis factor on HL-60 cells: cell-cycle specificity and synergism with Actinomycin-D. J Cell Physiol 1986; 130: 32833.
  • 52
    Larrick JW, Wright SC. Cytotoxic mechanisms of tumor necrosis factor-α. FASEB J 1990; 4: 321520.
  • 53
    Creasey AA, Reynolds MT, Laird W. Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor. Cancer Res 1986; 46: 568790.
  • 54
    Balkwill FR, Ward BG, Moodie E, Fiers W. Therapeutic potential of tumor necrosis factor α and τ interferon in experimental human ovarian cancer. Cancer Res 1987; 47: 47558.
  • 55
    Malik STA, Griffin DB, Fiers W, Balkwill FR. Paradoxical effects of tumor necrosis factor in experimental ovarian cancer. Int J Cancer 1989; 44: 91825.
  • 56
    Manetta A, Podezaski E, Zaino RJ, Satyaswaroop PG. Therapeutic effect of recombinant human necrosis factor in ovarian carcinoma xenograft in nude mice. Gynecol Oncol 1989; 34: 3604.
  • 57
    Spriggs DR, Yates SW. Cancer chemotherapy: experiences with TNF administration in humans. In: BeutlerB, editor. Tumor necrosis factors. New York: Raven Press, 1992: 383406.
  • 58
    Schiller JH, Witt PL, Storer B, Alberti D, Tombes MB, Arzoomanian R, et al. Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor. Cancer 1992; 69: 56271.
  • 59
    Young RC, Knapp RC, Fuks Z. Cancer of the ovary. In: De VitaVTJr., HellmanS, RosenbergSA, editors. Cancer: principles and practice of oncology. Philadelphia: JB Lippincott, 1985: 1083117.
  • 60
    Berek JS. Epithelial ovarian cancer. In: BerekJS, HackerNF, editors. Practical gynecologic oncology. Baltimore: Williams & Wilkins, 1989: 32764.